NodThera Limited

By 2040, over half a billion people could be taking GLP-1 agonists or other weight loss medicines, according to McKinsey. A market that barely existed prior to 2021 could be worth over $100bn by 2030

This year has posed substantial challenges for global markets: a prolonged period of high interest rates, ongoing geopolitical instability, democratic uncertainty, and an unprecedented number of natio

Anti-inflammatory drugs have come a long way since the advent of corticosteroids. While they marked a pivotal moment in the 20th century for managing devastating inflammation, non-steroidal anti-infla

NodThera Limited is focused on developing drugs that inhibit the NLRP3 inflammasome, a validated drug target that plays a pivotal role in controlling inflammatory diseases. It has two clinical trials